Nautilus, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Nautilus, Inc. (Ticker: NLS), now operating as BowFlex, Inc., designs, develops, sources, and markets cardio and strength fitness products and related accessories for consumer use in home and commercial settings; core offerings under the Bowflex brand include the Max Trainer, SelectTech adjustable dumbbells, Xtreme home gyms, Revolution home gyms, treadmills, ellipticals, and indoor cycling bikes; the Schwinn brand features upright bikes, indoor cycling bikes, treadmills, rowing machines, and the Classic Cruiser bike with digital app integration; the JRNY brand provides an adaptive digital fitness platform delivering real-time coaching, personalized workouts, motion tracking, and curated content via touchscreen or smart devices. The company operates through Direct and Retail segments, selling directly to consumers via e-commerce, television, catalogs, and call centers, and through independent retailers, with primary markets in the United States and Canada, and additional presence in Europe, the Middle East, Africa, and international regions. Founded in 1986 and headquartered in Vancouver, Washington, with facilities in Brooklyn Park, Minnesota; Shanghai, China; and distribution centers in Portland, Oregon; Columbus, Ohio; and Rotterdam, Netherlands, the company employs approximately 400-500 staff. In late 2023, Nautilus changed its name to BowFlex, Inc.; filed for Chapter 11 bankruptcy on March 5, 2024, amid post-pandemic demand normalization; and completed the sale of substantially all assets—including Bowflex, Schwinn, and JRNY brands—to Johnson Health Tech Retail, Inc. for $37.5 million cash in April 2024, following U.S. Bankruptcy Court approval, marking a major restructuring under new ownership while delisting from the NYSE.
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
NLS Pharmaceutics Ltd. and Kadimastem Ltd.
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients
Nautilus Biotechnology Reports Second Quarter 2025 Financial Results
NLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy
Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025
NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing
NLS Pharmaceutics CEO Issues Letter to Shareholders